Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CDC25B | P30305 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ERCC1 | P07992 | 2/20 | 0.37 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | PPIB | P23284 | 1/20 | 0.37 |
| ▸ | PPIA | P62937 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1852409 | 0.85 | HDAC1 (0.49) | HDAC1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL10891686 | 0.79 | ADRB2 (0.35) | CYP2C9CYP2C19HDAC1ALDH1A1KDM4E | |
| SCHEMBL2948305 | 0.77 | HDAC1 (0.48) | TSHRHDAC1HDAC3HDAC2CA1 | |
| SCHEMBL16370682 | 0.77 | TSHR (0.47) | CYP1A2CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL2729682 | 0.77 | HPGD (0.50) | CYP1A2CYP2C9TSHRALDH1A1CDC25B | |
| SCHEMBL1724603 | 0.76 | TSHR (0.50) | CYP1A2CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL2858938 | 0.76 | CYP2C9 (0.46) | CYP1A2CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL258716 | 0.75 | CYP2C9 (0.62) | CYP1A2CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL11533429 | 0.74 | CYP2C9 (0.65) | CYP1A2CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL10278361 | 0.74 | LOXL2 (0.39) | TSHRALDH1A1KDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230407293-A1 | DNA-ENCODED AND AFFINITY-TAGGED MASKED-WARHEAD COMPOUNDS AND USE THEREOF IN ASSEMBLING LIBRARIES OF SMALL MOLECULES ENABLED FOR LATE-STAGE PURIFICATION AND MULTIPLEXED SCREENING OF COVALENT LIGANDS | MAIANTI JUAN PABLO (US) | 2023-12-21 | — | — | US | disclosed |
| EP-2401275-B1 | NAPHTHYRIDINE DERIVATIVES HAVING BRONCHODILATING ACTIVITY | RESPIRATORIUS AB (SE) | 2013-07-24 | — | — | EP | disclosed |
| US-8415333-B2 | Bronchodilating diazaheteroaryls | RESPIRATORIOUS AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-8242116-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-08-14 | — | — | US | disclosed |
| US-20120040942-A1 | NOVEL BRONCHODILATING DIAZAHETEROARYLS | RESPIRATORIUS AB (SE) | 2012-02-16 | — | — | US | disclosed |
| EP-2401275-A1 | NOVEL BRONCHODILATING DIAZAHETEROARYLS | Respiratorius AB (SE) | 2012-01-04 | — | — | EP | disclosed |
| EP-2035436-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010097410-A1 | NOVEL BRONCHODILATING DIAZAHETEROARYLS | RESPIRATORIUS AB (SE) | 2010-09-02 | — | — | WO | disclosed |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230407293-A1 | DNA-ENCODED AND AFFINITY-TAGGED MASKED-WARHEAD COMPOUNDS AND USE THEREOF IN ASSEMBLING LIBRARIES OF SMALL MOLECULES ENABLED FOR LATE-STAGE PURIFICATION AND MULTIPLEXED SCREENING OF COVALENT LIGANDS | DNA2, WRN, DCLRE1A | CYP1A2 3212/4885CYP2D6 1981/4885CYP2C9 3083/4885 |
| US-20120040942-A1 | NOVEL BRONCHODILATING DIAZAHETEROARYLS | CHRM3, ADRB1, ADRB3 | CYP1A2 367/4885CYP2D6 356/4885CYP2C9 1216/4885 |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | CYP1A2 2905/4885CYP2D6 1689/4885CYP2C9 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.